Company news

Paradigm Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Paradigms AGM Presentation

November 26, 2018

Paradigm in-licenses treatment for rare joint disease

November 21, 2018

Paradigm receives $2.32m R&D tax incentive refund

November 14, 2018

PAR reports pain reduction in 145 people with osteoarthritis

November 7, 2018

Paradigm Agreement With USA Past Players Network

October 24, 2018

Paradigms Updated Corporate Presentation

October 24, 2018

Paradigm Raises A$9 Million

October 24, 2018

PAR reports pain reduction in OA patients

September 24, 2018

Phase2a RossRiver Virus Clinical Trial Recruitment Finalised

August 28, 2018

Appendix 4E and 2018 Annual Report

August 24, 2018

PAR achieves 60 per cent reduction in osteoarthritis pain

August 14, 2018

PAR achieves 100 per cent recruitment in Phase 2b OA Trial

August 5, 2018

PAR - 50% reduction in osteoarthritis pain maintained

June 14, 2018

Paradigm OA Phase 2b Clinical Trial over 80% Recruited

May 16, 2018

Paradigms phase 2 clinical data update

March 26, 2018

Paradigm reports osteoarthritis pain reduced by 50%

February 28, 2018

Half Year Accounts

February 22, 2018

Quarterly Update and Appendix 4C

January 29, 2018

PARs European Patent Granted for Bone Marrow Edema Lesions

January 15, 2018

Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule

November 22, 2017

Paradigms ACL Phase 2 Clinical Trial Success

November 13, 2017

PAR Successfully Completes A$5.75m Placement

November 5, 2017

First Participant Dosed in PARs Phase 2b OA Clinical Trial

October 29, 2017

PAR reports pain reduction in 83% of osteoarthritis patients

October 9, 2017

PARs Osteoarthritis Phase 2 Receives Ethics Approval

September 18, 2017

Paradigm Phase 2 Ross River Virus Clinical Trial Update

September 13, 2017

A Paradigm shift in treating osteoarthritis pain

September 10, 2017

Appendix 4E and 2017 Annual Report

August 29, 2017

Paradigm (PAR) - First Ross River Trial Participant Treated

August 8, 2017

Paradigm To Commence Phase 2 Ross River Virus Clinical Trial

July 9, 2017

Paradigm Enters Heart Failure Market

June 19, 2017

Hay Fever Trial Update

June 15, 2017

Paradigm Receives Ethics Approval for Ross River Trial

May 21, 2017

Paradigms preclinical hay fever trial published

May 15, 2017

Paradigm Government grant for Ross River virus research

May 10, 2017

Paradigm March Quarter Update & Appendix 4C

April 27, 2017

Final participant treated in Phase 2 hay fever trial

March 22, 2017

Paradigm receives $1.34 million R&D tax incentive rebate

March 21, 2017

Paradigm Update Ross River Virus Clinical Trial

March 7, 2017

Quarterly Cashflow Report

January 31, 2017

Recruitment complete in Paradigms hay fever clinical trial

January 24, 2017

Paradigms hay fever clinical trial cleared to commence

November 21, 2016

Appendix 4C - September 2016 quarter

October 28, 2016

Paradigms Placement heavily oversubscribed

October 17, 2016

Preclinical study underpins efficacy of Paradigms RhinosulR

September 15, 2016

Paradigm PPS a potential in the treatment of viral arthritis

September 6, 2016

Preliminary Final Report

August 31, 2016

Paradigm PPS nasal spray to treat Allergic Rhinitis

August 19, 2016

Shareholders Update

June 20, 2016

ASX Admission Market Release

June 20, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 30 decks. Every deck is listed under its year.